From Our Neurons to Yours

Why new Alzheimer's drugs don't work | Mike Greicius, Stanford University School of Medicine


Listen Later

In the past few years, Big Pharma has released not one, but three new treatments for Alzheimer’s disease.

Aducanemab (2021), Lecanemab (2023), and Donanemab (2024), are the first treatments to effectively clear the brain of amyloid plaques — the sticky protein clumps whose build-up in the brain has defined the disease for decades. The problem? They may not help patients at all.

Today’s guest, Stanford neurologist Mike Greicius, considers the new amyloid-clearing drugs a major disappointment — and worse, says they likely do more harm than good for patients.

Despite this critique, Greicius, thinks that the next few years will be an exciting time for novel Alzheimer’s therapies, as growing biological understanding of Alzheimer’s risk and resilience bear fruit with promising new approaches to treatment.

Learn More:

Greicius is the Iqbal Farrukh and Asad Jamal Professor of Neurology and Neurological Sciences at Stanford Medicine, and a member of the Knight Initiative for Brain Resilience and Alzheimer's Disease Research Center at Stanford University.

Amyloid Drug Skepticism:

  • Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies
    (Commentary, Journal of Alzheimer's Disease, 2024)
  • New Drug Approved for Early Alzheimer’s (New York Times, 2024)
  • Alzheimer's drug adoption in US slowed by doctors' skepticism (Reuters, 2024)
  • One step back: Why the new Alzheimer’s plaque-attack drugs don’t work (Stanford Medicine Scope Blog, 2024)

Alzheimer's Genetics Research:

  • Knight-funded research uncovers gene mutations that may prevent Alzheimer’s Disease (Knight Initiative for Brain Resilience, 2024)
  • Why is a common gene variant bad for your brain? (Stanford Medicine Magazine, 2024)
  • Scientists find genetic Alzheimer’s risk factor tied to African ancestry (Stanford Medicine, 2023)

Episode Credits

This episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

...more
View all episodesView all episodes
Download on the App Store

From Our Neurons to YoursBy Wu Tsai Neurosciences Institute at Stanford University, Nicholas Weiler

  • 5
  • 5
  • 5
  • 5
  • 5

5

24 ratings


More shows like From Our Neurons to Yours

View all
Science Magazine Podcast by Science Magazine

Science Magazine Podcast

810 Listeners

TED Health by TED

TED Health

1,425 Listeners

Hidden Brain by Hidden Brain, Shankar Vedantam

Hidden Brain

43,334 Listeners

The Daily by The New York Times

The Daily

110,602 Listeners

Up First from NPR by NPR

Up First from NPR

55,911 Listeners

The Future of Everything by Stanford Engineering

The Future of Everything

127 Listeners

Life Kit by NPR

Life Kit

4,351 Listeners

Fiction - Comedy Fiction by The Sunset Explorers

Fiction - Comedy Fiction

6,447 Listeners

Short Wave by NPR

Short Wave

6,210 Listeners

Chasing Life by CNN

Chasing Life

8,228 Listeners

Hard Fork by The New York Times

Hard Fork

5,462 Listeners

Unexplainable by Vox

Unexplainable

2,232 Listeners

Stanford Psychology Podcast by Stanford Psychology

Stanford Psychology Podcast

86 Listeners

Inner Cosmos with David Eagleman by iHeartPodcasts

Inner Cosmos with David Eagleman

578 Listeners

The Headlines by The New York Times

The Headlines

508 Listeners